Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

KRX:007570 Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	268,861	266,669	247,773	242,511	343,329
Other Revenue	-	-0	-0	-0	-
Revenue	268,861	266,669	247,773	242,511	343,329
Revenue Growth (YoY)	0.82%	7.63%	2.17%	-29.37%	5.78%
Cost of Revenue	157,461	150,265	139,579	137,865	161,690
Gross Profit	111,401	116,404	108,194	104,646	181,638
Selling, General & Admin	72,712	73,605	69,591	69,145	124,701
Research & Development	24,740	23,748	22,395	16,829	19,723
Other Operating Expenses	1,967	1,954	1,832	1,764	1,944
Operating Expenses	100,400	100,024	93,945	89,458	147,538
Operating Income	11,000	16,379	14,249	15,188	34,101
Interest Expense	-2,932	-3,225	-2,132	-1,894	-3,017
Interest & Investment Income	619.4	361.43	279.06	348.43	516.99
Earnings From Equity Investments	2,083	-13,425	10,754	9,236	-
Currency Exchange Gain (Loss)	1,222	-1,011	-551.53	1,265	-918.59
Other Non Operating Income (Expenses)	263.21	-928.6	1,288	-2,347	-354.03
EBT Excluding Unusual Items	12,256	-1,849	23,887	21,797	30,329
Gain (Loss) on Sale of Investments	27.78	8.92	-24.78	-	-123.55
Gain (Loss) on Sale of Assets	-8.96	0.53	21.22	2.86	134.47
Asset Writedown	2.15	40.51	-36.82	263.19	-1,947
Pretax Income	12,277	-1,799	23,846	22,063	28,393
Income Tax Expense	1,770	230.97	4,040	7,311	6,847
Earnings From Continuing Operations	10,508	-2,030	19,806	14,752	21,545
Minority Interest in Earnings	-250.39	-378.26	-420.96	-719.83	-10,666
Net Income	10,257	-2,409	19,385	14,032	10,880
Preferred Dividends & Other Adjustments	-	-	449.28	-	-
Net Income to Common	10,257	-2,409	18,936	14,032	10,880
Net Income Growth	-	-	38.15%	28.98%	8.96%
Shares Outstanding (Basic)	18	18	18	18	18
Shares Outstanding (Diluted)	18	18	18	18	18
Shares Change (YoY)	0.15%	1.44%	-0.44%	-	-
EPS (Basic)	557.00	-131.00	1044.71	770.78	597.61
EPS (Diluted)	557.00	-131.00	1036.00	770.78	597.00
EPS Growth	-	-	34.41%	29.11%	8.94%
Free Cash Flow	-32,585	8,736	1,938	39,057	47,310
Free Cash Flow Per Share	-1769.45	475.15	106.90	2145.40	2598.70
Gross Margin	41.43%	43.65%	43.67%	43.15%	52.91%
Operating Margin	4.09%	6.14%	5.75%	6.26%	9.93%
Profit Margin	3.82%	-0.90%	7.64%	5.79%	3.17%
Free Cash Flow Margin	-12.12%	3.28%	0.78%	16.11%	13.78%
EBITDA	20,824	28,350	26,016	26,415	46,765
EBITDA Margin	7.75%	10.63%	10.50%	10.89%	13.62%
D&A For EBITDA	9,824	11,971	11,767	11,227	12,664
EBIT	11,000	16,379	14,249	15,188	34,101
EBIT Margin	4.09%	6.14%	5.75%	6.26%	9.93%
Effective Tax Rate	14.41%	-	16.94%	33.14%	24.12%
Advertising Expenses	6,409	6,264	6,312	7,205	35,608

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.